Who is the CEO of RPbio?

According to the DART company overview, RPbio's representative director is 윤재훈 (name as registered in Korean). The company was founded on 2016-08-05.

Where is RPbio listed?

RPbio trades on the Korea Exchange KOSDAQ market under the ticker 314140. Its fiscal year ends in December.

Does RPbio pay a dividend?

Yes. For fiscal 2025, RPbio paid a cash dividend of ₩50 per common share, a 10.0% yield as stated in its annual report.

Does RPbio have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Profit +50% (latest quarterly operating profit up more than 50% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year); High dividend (reported dividend yield of 5% or more in the latest annual report). These are factual flags, not investment advice.

Which companies are in the same industry as RPbio?

Under the Korean Standard Industrial Classification recorded on DART, RPbio is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.

RPbio KRX:314140KOSDAQ

알피바이오 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days0

Articles tracked7since Sep 11

In Q2 2026, RPbio reported revenue of ₩39.8bn, up 11.4% year on year, and operating profit of ₩4.1bn. RPbio (알피바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.

Filing signals Profit +50% Revenue & profit growth High dividend Screener

RPbio quarterly results separate, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩39.8bn	+11.4%	₩4.1bn margin 10.3%	₩3.0bn
Q1 2026	₩35.1bn	+3.3%	₩2.4bn margin 6.9%	₩2.6bn
Q4 2025 derived	₩33.3bn	+6.4%	₩684m margin 2.1%	₩863m
Q3 2025	₩33.2bn	+18.2%	₩273m margin 0.8%	₩276m
Q2 2025	₩35.7bn	+11.3%	₩2.3bn margin 6.5%	₩1.8bn
Q1 2025	₩34.0bn	+4.6%	₩1.8bn margin 5.3%	₩1.7bn
Q4 2024 derived	₩31.3bn	-12.0%	₩357m margin 1.1%	₩1.1bn
Q3 2024	₩28.1bn	-32.3%	−₩1.3bn margin −4.5%	−₩1.6bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

RPbio top stories 2 weeks, by number of outlets

No story covered by multiple outlets in the past two weeks.

Latest RPbio news Korean headlines

Oct 617:29

알피바이오, ‘펙소페나딘 대용량 병포장’ 24개월 장기 보존 시험 완료
팍스경제TV
Oct 616:05

알피바이오, '펙소페나딘 대용량 병포장' 안정성 확보
핀포인트뉴스
Oct 614:27

알피바이오, 펙소페나딘 ‘제형+포장’ 투트랙…제품 확장
한스경제
Oct 610:56

알피바이오, 펙소페나딘 30캡슐 병포장 검증…24개월 보존시험 완료
메디컬투데이
Oct 608:58

알피바이오, 펙소페나딘 연질캡슐 30정 병포장 개발
메디파나뉴스
Sep 1508:43
[르포]“40년 노하우로 신제형 개발”…알피바이오, 해외 시장 정조준
이데일리
1 more on this story · 1 outlets
- [르포]“40년 노하우로 신제형 개발”…알피바이오, 해외 시장 정조준이데일리 · Sep 15 08:42

Articles per day 2 weeks

Company profile

CEO: 윤재훈
Industry: Pharmaceuticals
Founded: 2016-08-05
Fiscal year-end: December
Head office: 서울특별시 강남구
Website: rpskorea.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

RPbio dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩50	10.0%	–
FY2024	–	–	–
FY2023	₩50	10.0%	–

Same industry Pharmaceuticals

All in industry

Company	Latest quarter op. profit	Articles 30d
Hanmi Pharm	₩131bn	655
Yuhan	₩66.9bn	484
Daewoong Pharma	₩68.1bn	372
GC Biopharma	₩1.7bn	326
DongKookPharmaceutical	₩26.1bn	259
Daewon Pharmaceutical	−₩9m	197
Kwangdong Pharmaceutical	₩2.8bn	188
JW Pharmaceutical	₩33.3bn	185

Compare RPbio side by side with these companies

RPbio DART filings

No filings yet.

Mentioned alongside 2 weeks

No co-mentioned companies yet.

RPbio FAQ

Who is the CEO of RPbio?: According to the DART company overview, RPbio's representative director is 윤재훈 (name as registered in Korean). The company was founded on 2016-08-05.
Where is RPbio listed?: RPbio trades on the Korea Exchange KOSDAQ market under the ticker 314140. Its fiscal year ends in December.
What were RPbio's latest quarterly results?: In Q2 2026, RPbio reported revenue of ₩39.8bn, up 11.4% year on year, and operating profit of ₩4.1bn. Figures come from reports filed on DART.
Does RPbio pay a dividend?: Yes. For fiscal 2025, RPbio paid a cash dividend of ₩50 per common share, a 10.0% yield as stated in its annual report.
Does RPbio have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Profit +50% (latest quarterly operating profit up more than 50% year on year); Revenue & profit growth (latest quarterly revenue and operating profit both up more than 10% year on year); High dividend (reported dividend yield of 5% or more in the latest annual report). These are factual flags, not investment advice.
Which companies are in the same industry as RPbio?: Under the Korean Standard Industrial Classification recorded on DART, RPbio is grouped with 107 other listed companies in pharmaceuticals. The most covered in Korean news over the past 30 days are Hanmi Pharm, Yuhan and Daewoong Pharma.